Therapeutic recommendations for children with Hodgkin lymphoma
Therapeutic Recommendations for Children Registered in the RFAOP Register and With a Hodgkin Lymphoma
This study is trying to create a standard treatment plan for children with Hodgkin lymphoma to improve their care and reduce the side effects of radiation therapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 250 (estimated) |
| Ages | 0 Months to 18 Years |
| Sex | All |
| Sponsor | French Africa Pediatric Oncology Group Academic / other |
| Drugs / interventions | radiation, chemotherapy |
| Locations | 1 site (Paris, France) |
| Trial ID | NCT05407480 on ClinicalTrials.gov |
What this trial studies
This observational study aims to standardize staging and therapeutic recommendations for pediatric patients diagnosed with classical Hodgkin lymphoma. It focuses on developing treatment protocols based on clinical, biological, and radiological data, particularly in regions with varying access to radiation therapy. The study will involve collaboration among various pilot units in African countries to ensure consistent and effective treatment approaches. The goal is to improve therapeutic outcomes while minimizing the long-term effects of radiation therapy.
Who should consider this trial
Good fit: Ideal candidates for this study are children under 18 years of age diagnosed with classical Hodgkin lymphoma.
Not a fit: Patients over 18 years of age or those with a history of hematological malignancies or immune deficiencies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols that enhance survival rates and reduce long-term side effects for children with Hodgkin lymphoma.
How similar studies have performed: Other studies have shown success in standardizing treatment protocols for pediatric cancers, indicating that this approach has potential for positive outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: under 18 years of age at diagnosis * suffering from "classical" Hodgkin's disease according to the WHO classification. * with no history of hematological malignancies or constitutional or acquired immune deficiencies Exclusion Criteria: * Over 18 years of age at diagnosis * A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies
Where this trial is running
Paris, France
- Brenda Mallon — Paris, France, France (Recruiting)
Study contacts
- Principal investigator: FATEN Ben Ayed, Professeur — French Africa Pediatric Oncology Group
- Study coordinator: Brenda MS MALLON
- Email: brenda.mallon@gustaveroussy.fr
- Phone: 0033 142115411
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.